Authors


John Potthoff

Latest:

Eliminating ‘Disruption’ for Patients in Clinical Trials

Exploring new ways to smooth the path toward better participation for patients and other research and healthcare stakeholders.


Chirag Shah

Latest:

Regulatory Approval in India: An Updated Review

Issues concerning the drug approval process in India have occurred in clinical studies resulting in a reduced interest from sponsors. The Drug Controller General of India (DCGI) has been working to amend and update it’s policies to stimulate growth in this sector.


Kara Dennis

Latest:

Bring Your Own Device for Trial Outcome Assessment

Survey uncovers the challenges, myths, and potential useful strategies associated with BYOD adoption.


Company Press Release

Latest:

Syneos Health 2022 Health Trends

Insights from Syneos Health’s 2022 Health Trends: Insights for Industry Change Agent.


Heather Davis

Latest:

Planning for Success in Late Phase Global Oncology Trials

Following four key study-design steps is crucial to the delivery of a successful cross-border cancer study


Glenn Keet

Latest:

Sweeping Aside the Hurdles of EMR and EDC Integration

Historically, some longstanding challenges have hindered efforts to integrate patient data from EMRs (Electronic Medical Record systems) with EDC (Electronic Data Capture) systems.


Jessica Holden Kloda

Latest:

FDA’s Expedited Review Process: The Need for Speed

Outlining the requirements and benefits of FDA's four expedited drug approval pathways.


Shahza Somerville

Latest:

FDA’s Expedited Review Process: The Need for Speed

Outlining the requirements and benefits of FDA's four expedited drug approval pathways.


Jim Zhang, Ph.D

Latest:

Global Biomarker and Companion Diagnostics Outsourcing Market

Over recent years global drug companies large or small have recognized that one root cause of the high failure rate in their clinical development lies in the selection of right therapeutic targets.


Barbara A Ricker

Latest:

Evaluating the Effects of Therapy Masking

Using a specific trial, the importance of assessing the success of therapy masking is examined.


Alexander R Arslan

Latest:

Evaluating the Effects of Therapy Masking

Using a specific trial, the importance of assessing the success of therapy masking is examined.


Katherine M Seymour

Latest:

Evaluating the Effects of Therapy Masking

Using a specific trial, the importance of assessing the success of therapy masking is examined.


April Slee

Latest:

Evaluating the Effects of Therapy Masking

Using a specific trial, the importance of assessing the success of therapy masking is examined.


Jeffrey L Probstfield, MD

Latest:

Exploring the Role of the Regional Coordinator

How one large academic trial adopted a coordinating center model-helping drive early-model RBM gains


Suzanne Tran

Latest:

Where is the “Quality” in GCP?

Over the years, clinical study management has become more fragmented. There are more organizations participating in a study, each bringing their own experiences, interpretations of requirements including how quality is defined. How is it possible that requirements and quality be interpreted so differently?


Dante Ciambella

Latest:

Sentiment Analysis: Understand Your Healthcare Customers

 Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.


Laura Conti

Latest:

Sentiment Analysis: Understand Your Healthcare Customers

 Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.


Massimo Ruffolo

Latest:

Sentiment Analysis: Understand Your Healthcare Customers

 Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.


Umberto Scilinguo

Latest:

Sentiment Analysis: Understand Your Healthcare Customers

 Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.


Mimmo Garibbo

Latest:

Endpoint Adjudication of Events Charter Template: What Should Be Included?

Endpoint adjudication is gaining importance in pharma today, however, no guidance on endpoint adjudication currently exists. The LinkedIn Endpoint Adjudication Community has generated an Events Charter Template to shed light on the subject for those in need of guidance.


Miraj Barodia

Latest:

Business and People: September 2015

New faces among the Pharma Industry rise the ranks.


Kald Abdallah

Latest:

De-identifying Data in Clinical Trials

Whether we are referring to CSRs or to IPD, the personal information of trial participants needs to be de-identified prior to release. This article will describe the available methods for de-identifying clinical trial data, and the relative strengths and weaknesses of each.


Linda B. Sullivan

Latest:

Bridging the Gaps in CAPA Planning in Clinical Trials

Leveraging approaches in RBQM to enable effective corrective and preventive action processes.


Scott Kolodny

Latest:

Patient Safety Considerations for Follow-On Non-Biologic Complex Drugs

Biologic drugs and non-biologic complex drugs have revolutionized the treatment of many difficult-to-treat diseases including cancer, multiple sclerosis, and chronic iron deficiency.


Matthew Reaney

Latest:

Harnessing Patient-Centered Science to Improve Health Outcomes and Commercial Pharma Success

Good scientific principles and practices are essential for maintaining quality data that patients can benefit from.


Lawrence Z. Satin, MD

Latest:

Refined Safety Assessments

A case study of how cardiac safety assessments can be enhanced with Holter Bin.



Nataliia Vietchinkina

Latest:

Determining Participation in Ukraine

Survey shows what keeps Ukrainians away from clinical trials


Rob Wynden, PhD

Latest:

Speeding Clinical Trials Through eClinical Systems

Understanding the roles of eTMF, CTMS, and study startup solutions in the clinical trials process


Elvin Thalund

Latest:

The Challenge and Opportunity Presented by Clinical Trial Regulation EU 536/2014

New regulations offer opportunity for simplification in strategic planning.

© 2024 MJH Life Sciences

All rights reserved.